OnKure Therapeutics, Inc. OKUR Business Segments — Direct Program Expense

Similar metrics at other companies

LBR

LBRXClinical Trial — Direct Research And Development Expenses

$1.18M-88.8%

LBR

LBRXPreclinical And Other Direct Expenses — Direct Research And Development Expenses

$501K—

LBR

LBRXPreclinical — Direct Research And Development Expenses

$32.25K-93.0%

MPLTClinical Trial — Research And Development Expense

$24.82M+1,180%

CAMPR&D — Clinical and preclinical expenses

$4.63M+3.4%

GERNResearch and clinical expenses — R&D

$13M-5.1%

Questions, answered.

What is OnKure Therapeutics, Inc.'s business segments — direct program expense?

OnKure Therapeutics, Inc. (OKUR) reported business segments — direct program expense of $6.72M in Q1 2026.

How has OnKure Therapeutics, Inc.'s business segments — direct program expense changed year-over-year?

OnKure Therapeutics, Inc.'s business segments — direct program expense decreased by 14.7% year-over-year, from $7.87M to $6.72M.

What does business segments — direct program expense mean?

Represents the primary, traceable costs directly attributable to specific clinical trial programs and drug development activities. This includes expenses such as contract research organization fees, clinical site costs, and laboratory testing required for advancing therapeutic candidates. Monitoring this metric helps investors assess the capital intensity of the company's core R&D pipeline.